Anhui Sunhere Pharmaceutical Excipients Co Ltd (300452) - Net Assets
Based on the latest financial reports, Anhui Sunhere Pharmaceutical Excipients Co Ltd (300452) has net assets worth CN¥1.12 Billion CNY (≈ $164.21 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.76 Billion ≈ $257.17 Million USD) and total liabilities (CN¥635.27 Million ≈ $92.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300452 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.12 Billion |
| % of Total Assets | 63.85% |
| Annual Growth Rate | 18.82% |
| 5-Year Change | 52.1% |
| 10-Year Change | 166.62% |
| Growth Volatility | 24.32 |
Anhui Sunhere Pharmaceutical Excipients Co Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Anhui Sunhere Pharmaceutical Excipients Co Ltd's net assets have evolved over time, based on quarterly financial data. See Anhui Sunhere Pharmaceutical Excipients defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Anhui Sunhere Pharmaceutical Excipients Co Ltd (2011–2025)
The table below shows the annual net assets of Anhui Sunhere Pharmaceutical Excipients Co Ltd from 2011 to 2025. For live valuation and market cap data, see Anhui Sunhere Pharmaceutical Excipients (300452) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.07 Billion ≈ $157.12 Million |
+10.09% |
| 2024-12-31 | CN¥975.30 Million ≈ $142.72 Million |
+4.28% |
| 2023-12-31 | CN¥935.25 Million ≈ $136.86 Million |
+18.59% |
| 2022-12-31 | CN¥788.62 Million ≈ $115.40 Million |
+11.72% |
| 2021-12-31 | CN¥705.92 Million ≈ $103.30 Million |
+7.75% |
| 2020-12-31 | CN¥655.17 Million ≈ $95.87 Million |
+9.82% |
| 2019-12-31 | CN¥596.57 Million ≈ $87.30 Million |
+6.93% |
| 2018-12-31 | CN¥557.89 Million ≈ $81.64 Million |
+11.53% |
| 2017-12-31 | CN¥500.23 Million ≈ $73.20 Million |
+24.22% |
| 2016-12-31 | CN¥402.70 Million ≈ $58.93 Million |
+10.88% |
| 2015-12-31 | CN¥363.20 Million ≈ $53.15 Million |
+104.97% |
| 2014-12-31 | CN¥177.20 Million ≈ $25.93 Million |
+18.74% |
| 2013-12-31 | CN¥149.23 Million ≈ $21.84 Million |
+23.16% |
| 2012-12-31 | CN¥121.17 Million ≈ $17.73 Million |
+26.26% |
| 2011-12-31 | CN¥95.96 Million ≈ $14.04 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Anhui Sunhere Pharmaceutical Excipients Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1565.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥577.44 Million | 57.36% |
| Other Components | CN¥429.22 Million | 42.64% |
| Total Equity | CN¥1.01 Billion | 100.00% |
Anhui Sunhere Pharmaceutical Excipients Co Ltd Competitors by Market Cap
The table below lists competitors of Anhui Sunhere Pharmaceutical Excipients Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Costamare Bulkers Holdings Limited
NYSE:CMDB
|
$408.65 Million |
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
|
$408.71 Million |
|
Shenzhen Sunyes Electronic Manufacturing Holding Co Ltd
SHE:002388
|
$408.78 Million |
|
Aurora Corp
TW:2373
|
$408.78 Million |
|
Key Ware Electronics Co Ltd
TWO:5498
|
$408.60 Million |
|
Wuhan Nusun Landscape Co Ltd
SHE:300536
|
$408.57 Million |
|
Gladstone Capital Corporation
NASDAQ:GLAD
|
$408.48 Million |
|
Cross Country Healthcare Inc
NASDAQ:CCRN
|
$408.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anhui Sunhere Pharmaceutical Excipients Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 905,009,796 to 1,006,655,015, a change of 101,645,219 (11.2%).
- Net income of 176,552,467 contributed positively to equity growth.
- Dividend payments of 71,429,876 reduced retained earnings.
- Other comprehensive income decreased equity by 105,391,879.
- Other factors increased equity by 101,914,506.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥176.55 Million | +17.54% |
| Dividends Paid | CN¥71.43 Million | -7.1% |
| Other Comprehensive Income | CN¥-105.39 Million | -10.47% |
| Other Changes | CN¥101.91 Million | +10.12% |
| Total Change | CN¥- | 11.23% |
Book Value vs Market Value Analysis
This analysis compares Anhui Sunhere Pharmaceutical Excipients Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.77x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 21.82x to 2.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.55 | CN¥11.91 | x |
| 2012-12-31 | CN¥0.68 | CN¥11.91 | x |
| 2013-12-31 | CN¥0.85 | CN¥11.91 | x |
| 2014-12-31 | CN¥1.00 | CN¥11.91 | x |
| 2015-12-31 | CN¥1.62 | CN¥11.91 | x |
| 2016-12-31 | CN¥1.73 | CN¥11.91 | x |
| 2017-12-31 | CN¥1.87 | CN¥11.91 | x |
| 2018-12-31 | CN¥2.08 | CN¥11.91 | x |
| 2019-12-31 | CN¥2.25 | CN¥11.91 | x |
| 2020-12-31 | CN¥2.54 | CN¥11.91 | x |
| 2021-12-31 | CN¥2.72 | CN¥11.91 | x |
| 2022-12-31 | CN¥3.10 | CN¥11.91 | x |
| 2023-12-31 | CN¥3.59 | CN¥11.91 | x |
| 2024-12-31 | CN¥3.86 | CN¥11.91 | x |
| 2025-12-31 | CN¥4.29 | CN¥11.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anhui Sunhere Pharmaceutical Excipients Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.54%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.73%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.70x
- Recent ROE (17.54%) is above the historical average (17.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 22.76% | 15.25% | 1.18x | 1.27x | CN¥12.25 Million |
| 2012 | 26.54% | 17.49% | 0.87x | 1.75x | CN¥20.05 Million |
| 2013 | 23.47% | 16.45% | 0.91x | 1.57x | CN¥20.10 Million |
| 2014 | 19.71% | 14.59% | 0.90x | 1.50x | CN¥17.21 Million |
| 2015 | 12.19% | 17.10% | 0.57x | 1.26x | CN¥7.95 Million |
| 2016 | 12.11% | 17.03% | 0.56x | 1.27x | CN¥8.52 Million |
| 2017 | 11.40% | 14.83% | 0.51x | 1.51x | CN¥6.19 Million |
| 2018 | 14.22% | 16.36% | 0.60x | 1.44x | CN¥20.80 Million |
| 2019 | 16.05% | 18.18% | 0.57x | 1.54x | CN¥31.79 Million |
| 2020 | 16.05% | 17.69% | 0.59x | 1.54x | CN¥35.42 Million |
| 2021 | 13.95% | 14.47% | 0.64x | 1.50x | CN¥25.25 Million |
| 2022 | 18.09% | 18.55% | 0.60x | 1.63x | CN¥58.46 Million |
| 2023 | 18.65% | 19.25% | 0.54x | 1.78x | CN¥74.93 Million |
| 2024 | 13.20% | 13.53% | 0.57x | 1.72x | CN¥28.92 Million |
| 2025 | 17.54% | 18.73% | 0.55x | 1.70x | CN¥75.89 Million |
Industry Comparison
This section compares Anhui Sunhere Pharmaceutical Excipients Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,988,841
- Average return on equity (ROE) among peers: 4.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anhui Sunhere Pharmaceutical Excipients Co Ltd (300452) | CN¥1.12 Billion | 22.76% | 0.57x | $408.61 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $654.09 Million | 2.17% | 0.78x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $307.22 Million | 6.68% | 0.79x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.55 Billion | 4.67% | 3.16x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $25.04 Billion | 7.11% | 0.16x | $3.00 Billion |
About Anhui Sunhere Pharmaceutical Excipients Co Ltd
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. research and development, production, and sale of new pharmaceutical excipients in China. The company provides cellulose, starch, povidone, stearic acid, coating powder, resin, food additive, and other products. It also exports its products. Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. was founded in 2001 and is based in Huainan, China.